Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

NCT00372567 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

69

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Gastrointestinal Stromal Tumor

Interventions

DRUG: sunitinib malate
DRUG: imatinib mesylate

Sponsor

Pfizer